SEC Info - Acorda Therapeutics, Inc.

SEC Info℠

Home

Help

Please Sign In

Acorda Therapeutics, Inc. – ‘8-K’ for 3/7/24

On: Wednesday, 3/13/24, at 4:30pm ET · For: 3/7/24 · Accession #: 950170-24-30816 · File #: 1-31938

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/13/24  Acorda Therapeutics, Inc.         8-K:5,9     3/07/24    9:291K                                   Donnelley … Solutions/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     40K 
 2: EX-3.1      Articles of Incorporation/Organization or Bylaws    HTML    121K 
 4: R1          Document And Entity Information                     HTML     48K 
 6: XML         IDEA XML File -- Filing Summary                      XML     11K 
 9: XML         XBRL Instance -- acor-20240307_htm                   XML     16K 
 5: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 3: EX-101.SCH  XBRL Taxonomy Extension Schema With Embedded         XSD     75K 
                Linkbases Document -- acor-20240307                              
 7: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    18K 
 8: ZIP         XBRL Zipped Folder -- 0000950170-24-030816-xbrl      Zip     32K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX:

8-K

i 0001008848 i --12-31 i false00010088482024-03-072024-03-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i March 07, 2024

i Acorda Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)


i Delaware	i 001-31938	i 13-3831168
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

i 2 Blue Hill Plaza i 3rd Floor
i Pearl River, i New York		i 10965
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: i 914 i 347-4300

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Common Stock, par value $0.001 per share	i ACOR	i Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On March 7, 2024, the Board of Directors of Acorda Therapeutics, Inc. (the “Company”) adopted amendments to the Company’s Bylaws (the “Amended and Restated Bylaws”), which became effective immediately. The Amended and Restated Bylaws enhance disclosure and procedural requirements for the nomination of directors by stockholders, including to require compliance with the notice and solicitation requirements of Rule 14a-19 under the Securities Exchange Act of 1934. The amendments also update various provisions of the Bylaws to reflect recent amendments to the General Corporation Law of the State of Delaware, including the elimination of a provision requiring that a list of stockholders be available for inspection during meetings of stockholders and certain changes to the manner in which meetings of stockholders may be adjourned. The amendments also include a number of clerical and conforming changes.

The foregoing description of the Amended and Restated By-Laws does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended and Restated By-Laws, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description
3.1		Amended and Restated By-Laws of Acorda Therapeutics, Inc., effective March 7, 2024.
104		Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			Acorda Therapeutics, Inc.

Date:	March 13, 2024	By:	/s/ *Michael A. Gesser*
			Michael A. Gesser Chief Financial Officer and Treasurer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on:	3/13/24	None on these Dates
For Period end:	3/7/24
		List all Filings

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/01/24  Acorda Therapeutics, Inc.         10-K       12/31/23  110:17M                                    Donnelley … Solutions/FA

↑Top

Filing Submission 0000950170-24-030816 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)